DiaMedica Appoints New Chief Medical Officer

Diamedica Therapeutics ( (DMAC) ) just unveiled an update.

On August 4, 2025, Lorianne Masuoka resigned as Chief Medical Officer of DiaMedica Therapeutics for personal reasons, with a separation agreement providing health benefits through October 2026. Julie Krop was appointed as the new Chief Medical Officer, effective August 11, 2025, bringing over 20 years of experience in biotech and pharmaceuticals. Her appointment is seen as a strategic move to advance DiaMedica’s clinical development, particularly for DM199, a promising treatment for preeclampsia and acute ischemic stroke.

The most recent analyst rating on (DMAC) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.

Spark’s Take on DMAC Stock

According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.

Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.

To see Spark’s full report on DMAC stock, click here.

More about Diamedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious ischemic diseases, particularly preeclampsia, fetal growth restriction, and acute ischemic stroke. Its lead candidate, DM199, is a synthetic form of the KLK1 protein, used in Asia for treating these conditions.

Average Trading Volume: 275,257

Technical Sentiment Signal: Buy

Current Market Cap: $232.1M

For a thorough assessment of DMAC stock, go to TipRanks’ Stock Analysis page.